Letter to the Editor: Efficacy and safety of the generic forms of sofosbuvir/ledipasvir in chronic hepatitis C virus adolescents in Upper Egypt
World Journal of Hepatology·
- DOI
- 10.4254/wjh.118661
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Baishideng Publishing Group Inc.
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The authors support use of generic sofosbuvir/ledipasvir in children and adolescents in Egypt and other resource-limited countries. This relevance reflects the authors' stated position and the reported study findings.
Structured evidence summary
Research question
The article discusses the efficacy and safety of generic sofosbuvir/ledipasvir for adolescents with chronic hepatitis C in Upper Egypt.
Study design
This is a letter to the editor that summarizes a prior 2021 study in adolescents and refers to a separate retrospective study comparing generic and branded treatment. The supplied abstract does not provide detailed methods for the 2021 study.
Population and setting
The discussed population comprised adolescents with chronic hepatitis C treated at Assiut in Upper Egypt, including treatment-naive patients with or without hematological disorders and patients who had not responded to pegylated interferon/ribavirin.
Main findings
The abstract reports a sustained virologic response at 12 weeks of 100% in each of the described patient groups. Treatment was reported as well tolerated, with minimal side effects.
Public-health relevance
The authors support use of generic sofosbuvir/ledipasvir in children and adolescents in Egypt and other resource-limited countries. This relevance reflects the authors' stated position and the reported study findings.
Important limitations
The supplied material is a single-article abstract and metadata record, and it does not provide the full methods, sample size, comparator details, follow-up beyond the reported SVR12 measure, or detailed adverse-event data. The original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable as a hepatitis C treatment report concerning Egypt and adolescents, with relevance to generic sofosbuvir/ledipasvir. The supplied evidence provides literature context only and does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.